ReviewClinical chemistry2012
Next steps in cardiovascular disease genomic research--sequencing, epigenetics, and transcriptomics.
Review in Clinical chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bicuspid aortic valve aortopathy: genetics, pathophysiology and medical therapy.Interactive cardiovascular and thoracic surgery · 2013Pooled it
- Polygenic Risk Score for Cardiovascular Diseases in Artificial Intelligence Paradigm: A Review.Journal of Korean medical science · 2023Review
- Review
- Differential DNA Methylation and Cardiometabolic Risk in African American Mother-Adolescent Dyads.Biological research for nursing · 2022Article
- Current Understanding of piRNA in Cardiovascular Diseases.Frontiers in molecular medicine · 2021Review
- Epigenetic Regulation of Vascular Diseases.Arteriosclerosis, thrombosis, and vascular biology · 2019Review
- Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.Non-coding RNA · 2019Article
- Nutrigenomics, the Microbiome, and Gene-Environment Interactions: New Directions in Cardiovascular Disease Research, Prevention, and Treatment: A Scientific Statement From the American Heart Association.Circulation. Cardiovascular genetics · 2016Review
- Network-Based Identification and Prioritization of Key Regulators of Coronary Artery Disease Loci.Arteriosclerosis, thrombosis, and vascular biology · 2016Article
- Microbiome-Epigenome Interactions and the Environmental Origins of Inflammatory Bowel Diseases.Journal of pediatric gastroenterology and nutrition · 2016Review
- Systems Medicine as an Emerging Tool for Cardiovascular Genetics.Frontiers in cardiovascular medicine · 2016Review
- Cardiovascular transcriptomics and epigenomics using next-generation sequencing: challenges, progress, and opportunities.Circulation. Cardiovascular genetics · 2014Review
- Quantitative proteomics in cardiovascular research: global and targeted strategies.Proteomics. Clinical applications · 2014Review
- Genetic screening for the risk of type 2 diabetes: worthless or valuable?Diabetes care · 2013Review
- Personalized cardiovascular medicine: concepts and methodological considerations.Nature reviews. Cardiology · 2013Review
- Impact of pyrrolidine-bispyrrole DNA minor groove binding agents and chirality on global proteomic profile in Escherichia Coli.Proteome science · 2013Article
- Genomics in cardiovascular disease.Journal of the American College of Cardiology · 2013Review
- Highlights of the 2012 Research Workshop: Using nutrigenomics and metabolomics in clinical nutrition research.JPEN. Journal of parenteral and enteral nutrition · 2013Article
- Associations between dietary patterns and gene expression profiles of healthy men and women: a cross-sectional study.Nutrition journal · 2013Article
- Network topology reveals key cardiovascular disease genes.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGenomic research in cardiovascular disease (CVD) has progressed rapidly over the last 5 years. In most cases, however, these groundbreaking observations have not yet been accompanied by clinically applicable tools for risk prediction, diagnosis, or therapeutic interventions. CONTENT: We reviewed the scientific literature published in English for novel methods and promising genomic targets that would permit large-scale screening and follow-up of recent genomic findings for CVD. We anticipate that advances in 3 key areas will be critical for the success of these projects. First, exome-centered and whole-genome next-generation sequencing will identify rare and novel genetic variants associated with CVD and its risk factors. Improvements in methods will also greatly advance the field of epigenetics and gene expression in humans. Second, research is increasingly acknowledging that static DNA sequence variation explains only a fraction of the inherited phenotype. Therefore, we expect that multiple epigenetic and gene expression signatures will be related to CVD in experimental and clinical settings. Leveraging existing large-scale consortia and clinical biobanks in combination with electronic health records holds promise for integrating epidemiological and clinical genomics data. Finally, a systems biology approach will be needed to integrate the accumulated multidimensional data. SUMMARY: Novel methods in sequencing, epigenetics, and transcriptomics, plus unprecedented large-scale cooperative efforts, promise to generate insights into the complexity of CVD. The rapid accumulation and integration of knowledge will shed light on a considerable proportion of the missing heritability for CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.